An interventional study of FAPI PET CT in High Grade Serous Ovarian Cancer (HGSOC), sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Ovarian Neoplasms by University Health Network, Toronto — 6 open to participants now, 12 under way, 1 of them phase 3. Ovarian Neoplasms · University Health Network, Toronto.
Among the 21 studies in Ovarian Neoplasms by University Health Network, Toronto, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 18th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →6 of the 21 studies in Ovarian Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Women only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Women only
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+ · Healthy volunteers
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 32 across the 16 interventional studies, 310 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
5 of the studies in Ovarian Neoplasms by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02869217University Health Network, TorontoStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | 2026-11 |
| NCT02732860University Health Network, TorontoPersonalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | 2027-01-04 |
| NCT06459271University Health Network, TorontoFeasibility of CALM in Patients With Ovarian Cancer | 2027-02 |
| NCT03702309University Health Network, TorontoLiquid Biopsy Evaluation and Repository Development at Princess Margaret | 2027-07-06 |
| NCT05956093University Health Network, Toronto68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study | 2027-09-25 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies in Ovarian Neoplasms by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
The purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans.
The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
The purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans. The radiopharmaceutical ("radiotracer") 68Ga-PNT6555 (FAPI) is experimental. Experimental means Health Canada has not approved the sale or use of 68Ga-PNT6555 (FAPI), but they have approved its use in this research study.
About 30 patients will take part in this study, and estimate it will take up to 3 years to complete the study enrollment.
Our primary goal is to determine if high-grade epithelial ovarian cancers have a strong affinity for 68Ga-PNT6555, which is a Fibroblast activation protein inhibitor also known as FAPI.
Our secondary objectives: Compare Positron Emission Tomography (PET) scan to CT (computerized tomography) and surgical findings, check FAPI uptake after chemotherapy and assess 68Ga-PNT6555 safety.
The Tertiary objectives aim to achieve are to detect residual disease with FAPI PET after primary cytoreduction, assess expression variation at different tumour sites, and determine correlations between FAP tumour volumes and clinical parameters such as cytoreduction, Progression-free survival (PFS), and overall survival (OS).
This study focuses on individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV. These individuals must also be considered for primary cytoreductive surgery or neoadjuvant chemotherapy. During the study, patients will undergo a PET/CT scan at the outset and a follow-up scan within six weeks of the screening.
For those who are receiving chemotherapy and then interval cytoreductive surgery, additional scans will be scheduled. Patients who have undergone complete cytoreduction can arrange a scan four weeks after the surgery.
In order to participate in this study, certain criteria must be met. These include being at least 18 years of age, having received a diagnosis of HGSOC via cytology or histology, or having clinical suspicion of HGSOC based on various factors such as symptoms, physical exam, tumour markers, and imaging findings. It is also necessary to have clinical stage III or IV, be considered for primary Cytoreductive Surgery(PCS)or NACT, and have had a contrast-enhanced CT abdomen and pelvis within 6 weeks of PET prior to enrolling. Informed consent and adherence to PET examination safety guidelines are required for participation in this study. Eligibility criteria include the absence of pregnancy, the ability to remain still during the exam, and the absence of certain types of ovarian cancer or advanced gynecological malignancy, such as mucinous, low-grade serous, low-grade endometrioid, and low-malignant potential tumours. Throughout the procedure, patients who are receiving 68Ga-PNT6555 will be injected with a precisely measured dose of 120-220 MBq(Mega Becquerel - Unit of activity of a quantity of radioactive material)(3.2-5.9 mCi) via a syringe over a period of 5-10 seconds. Following that, they will undergo a 60-120-minute uptake time and are required to drink 750 mL of dilute water-soluble oral contrast, which is a standard protocol for PET/CT in abdominal malignancies. A low-dose CT scan will be obtained from mid-skull to mid-thigh, followed by 3D PET acquisition. Attenuation correction and emission reconstruction will be carried out according to standard clinical practices. The scan parameters will be meticulously documented in accordance with departmental guidelines. Patient safety will be closely monitored throughout the scanning session and up to 2 hours after the radiopharmaceutical injection. Prior to taking part in the research, all potential candidates will undergo a thorough screening process to verify their eligibility. Following this, they will sign an Informed Consent Form and the Clinical research Coordinator( CRC) will complete a registration checklist. The PI will closely oversee the clinical research coordinator's management of data and record keeping to guarantee that they are precise, comprehensive, easy to read, and punctual. Based on the limited clinical experience with 68Ga-PNT6555, the risk of significant side effects is low. Available information indicates that over 100 patients who received a similar dye reported no side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients will be eligible for inclusion in this study if they meet the following criteria:
Exclusion Criteria:
Patients will be ineligible to participate in this study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.
Radiation: FAPI PET CT
the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
FAPI positivity
A lesion will be considered abnormal when focal tracer accumulation is greater than background activity and cannot be attributed to a physiological or benign entity.FAPI tumour volumes will be correlated with clinical outcome measures including: 1. Achievement of optimal or complete cytoreduction; 2. Progression-free survival (PFS); 3. Overall survival (OS).
Time frame: through study completion, an average of 1 year
Quantitative parameters
Comparison of tracer uptake (SUVmax/mean) in a lesion to reference tissues (blood pool, liver); calculation of ratio of lesion SUV/ reference tissues.
Time frame: through study completion, an average of 1 year
Modality performance measures (CT vs PET)
Sensitivity, specificity, Negative Predictive Value (NPV), Positive Predictive Value (PPV) and validity will be calculated for each modality according to the reference standard (surgery and surgical histopathology) for all evaluable lesions.
Time frame: through study completion, an average of 1 year
Frequency of AE's
Safety Measurements
Time frame: through study completion, an average of 1 year
Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.
Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 36 months is below that.
Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Sep 2024, on Sep 28, 2026.
Primary completion moved twice since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2027, last on Nov 2, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: May 2026 → Dec 2027, last on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →